Evidence map›Paper›PMID 40597122›Full record

ArticleBMC pediatrics2025

Paxlovid for the treatment of severe or critical COVID-19 in children.

Linjuan Xiang, Qun Wang, Yanwen Xu, Yu Tong, Yuhang Wu, Xiaoshan Zhang, Xinxin Zeng, Sheng Ye, Chenmei Zhang, Linhua Tan and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Linjuan Xiang *Department of Infectious Disease, Children's Hospital, School of Medicine, Zhejiang University, National Clinical Research Center for Child Health, Hangzhou, 310052, China.
Qun Wang *Department of Infectious Disease, Children's Hospital, School of Medicine, Zhejiang University, National Clinical Research Center for Child Health, Hangzhou, 310052, China.
Yanwen Xu *Department of Infectious Disease, Children's Hospital, School of Medicine, Zhejiang University, National Clinical Research Center for Child Health, Hangzhou, 310052, China.
Yu TongDepartment of Infectious Disease, Children's Hospital, School of Medicine, Zhejiang University, National Clinical Research Center for Child Health, Hangzhou, 310052, China.
Yuhang WuDepartment of Infectious Disease, Children's Hospital, School of Medicine, Zhejiang University, National Clinical Research Center for Child Health, Hangzhou, 310052, China.
Xiaoshan ZhangDepartment of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China.
Xinxin ZengDepartment of Infectious Disease, Children's Hospital, School of Medicine, Zhejiang University, National Clinical Research Center for Child Health, Hangzhou, 310052, China.
Sheng YeDepartment of Pediatric Intensive Care Unit, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, 310052, China.
Chenmei ZhangDepartment of Pediatric Intensive Care Unit, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, 310052, China.
Linhua TanDepartment of Surgical Intensive Care Unit, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, 310052, China.
Lvchang ZhuDepartment of Pediatric Intensive Care Unit, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, 310052, China.
Jing MiaoDepartment of Pharmacy, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, 310052, China.
Sun ChenDepartment of Pediatric Cardiology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.
Xi ZhangClinical Research Unit, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.
Xuben YuDepartment of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China. xubenyu@wmu.edu.cn.
Lisu HuangDepartment of Infectious Disease, Children's Hospital, School of Medicine, Zhejiang University, National Clinical Research Center for Child Health, Hangzhou, 310052, China. lisuhuang@zju.edu.cn.

Funding

the National Key Research and Development Program of China 2021YFC2701800, 2021YFC2701801
6 · The paper itself

Abstract

backgroundPaxlovid, known for its efficacy against SARS-CoV-2, is currently limited in its use for treating pediatric COVID-19, particularly in severe or critical cases.

methodsWe conducted a study within a single-center, prospective cohort of 450 children diagnosed with COVID-19 between December 2022 and May 2023. This study included 30 pediatric patients who received Paxlovid and 60 matched controls who did not, based on factors such as age, disease severity, and underlying health conditions. Safety was assessed through the incidence of adverse events, and laboratory parameters. The time to clinical symptom improvement was the main efficacy outcome. Moreover, we calculated the AUC

resultsAdverse events occurred in 16.7% of both groups, with no serious events reported. The Paxlovid group showed a significantly shorter time to viral clearance, fever resolution, and symptom recovery compared to controls (4.9 vs. 11.0 days, P = 0.01; 11.2 vs. 16.4 days, P = 0.01; 4.6 vs. 17.6 days, P < 0.01). This effect was most noticeable in children with underlying conditions or those treated early. No significant differences were observed in ICU transfers or mortality (P > 0.05). The AUC₀-₁₂

conclusionOur findings suggest that Paxlovid may be a safe and effective option for treating severe or critical COVID-19 in children.

Indexed as

Antiviral AgentsCOVID-19 Drug TreatmentAdolescentCase-Control StudiesChildChild, PreschoolCOVID-19Critical IllnessFemaleHumansInfantMaleProspective StudiesSARS-CoV-2Severity of Illness IndexTreatment OutcomeAntiviral AgentsChildrenCOVID-19CriticalPaxlovidPharmacokinetics

Identifiers

PMID40597122
PMCPMC12220247

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.